



RE-Solve@

Remote **E**vent on **SOL**utions for **V**enous and **@**rterial diseases

July: Tuesday, 13th and 20th

October: Thursday 7th, 14th, 21st

Scientific board:

Professor A.Nicolaides

Professor G.Palareti

www.re-solve.expert



EACCME (LEE21-00681; LEE21-00686)

July: **Tuesday, 13th** Focus on CVD and Phlebo-lymphology
6.00-8.00 pm (CEST)

Plenary room: Challenges in clinical and procedural settings of Phlebology

- 6.00** • Opening: current challenges in Phlebology - **A. Nicolaides (CY)**
Q&A - Moderator: **J.D. Raffetto (US)** • Discussant: **A. Gonzalez Ochoa (MX)**
- 6.20** • Which drivers in Varicose Veins development, lymphatics involvement and skin changes progression? - **J.D. Raffetto (US)**
Q&A - Moderator: **T. Urbanek (PL)** • Discussant: **L. Zhang (CN)**
- 6.40** • Thrombotic risk in Varicose Veins and Pelvic Venous Disease - **S. Giancesini (IT)**
Q&A - Moderator: **Z. Lazarashvili (GE)** • Discussant: **P.L. Antignani (IT)**

EACCME (LEE21-00681)

Breakout A: New insights in the clinical management of CVD

- 7.00** • Medical target in Chronic Venous Disease: what's new? - **F. Mannello (IT)**
Q&A - Moderator: **J.D. Raffetto (US)** • Discussant: **R. Rial (SP)**
- 7.20** • Effects on inflammation of Sulodexide in animal model of CVD - **E. Bouskela (BR)**
Q&A - Moderator: **L. Chernukha (UA)** • Discussant: **N. Lecuona (MX)**
- 7.40** • First in human lymphatic Glycocalyx identification and clinical implication - **S. Giancesini (IT)**
Q&A - Moderator: **S. Rockson (US)** • Discussant: **J. Strejcek (CZ)**
- 7.55** • Take Home Messages - **J.D. Raffetto (US)**

EACCME (LEE21-00686)

Breakout B: New insights in procedural Phlebology

- 7.00** • New insights in Phlebology - **A. Zielinski (PL)**
Q&A - Moderator: **S. Flores (MX)** • Discussant: **M.N. Hassairi (TN)**
- 7.20** • Management in peri-procedural endovenous treatment of VVs - **A. Gonzalez Ochoa (MX)**
Q&A - Moderator: **A. Nicolaides (CY)** • Discussant: **S. Olariu (RO)**
- 7.40** • Thrombotic risk management in Phlebology - **T. Urbanek (PL)**
Q&A - Moderator: **J. Caprini (US)** • Discussant: **J. Serralde (MX)**
- 7.55** • Take Home Messages - **T. Urbanek (PL)**

EACCME (LEE21-00171; LEE21-00718)

July: **Tuesday, 20th** Focus on VTE and PTS

6.00-8.00 pm (CEST)

Plenary room: Challenges in clinical and procedural settings of VTE and PTS

- 6.00** • Opening: current challenges in VTE – P. Prandoni (IT)
Q&A - Moderator: G. Palareti (IT) • Discussant: J. Caprini (US)
- 6.20** • Which prognostic factors from PTS? – M. Monreal (SP)
Q&A - Moderator: S. Kakkos (GR) • Discussant: G. Palareti (IT)
- 6.40** • Net Clinical Benefit in VTE management – G. Palareti (IT)
Q&A - Moderator: A. Nicolaides (CY) • Discussant: J. Matuska (CZ)

EACCME (LEE21-00171)

Breakout A: New insights in the management of VTE

- 7.00** • New targets in VTE management – J. Caprini (US)
Q&A - Moderator: P. Prandoni (IT) • Discussant: Y. Li (CN)
- 7.20** • Thromboinflammation in VTE pathogenesis – F. Mannello (IT)
Q&A - Moderator: Y. Li (CN) • Discussant: A. Gonzalez Ochoa (MX)
- 7.40** • COVID related VTE risk management – A. Gonzalez Ochoa (MX)
Q&A - Moderator: G. Palareti (IT) • Discussant: J. Caprini (US)
- 7.55** • Take Home Messages – P. Prandoni (IT)

EACCME (LEE21-00718)

Breakout B: New insights in the management of PTS

- 7.00** • New insights from International Guidelines – S. Kakkos (GR)
Q&A - Moderator: A. Nicolaides (CY) • Discussant: G. Sokurenko (RU)
- 7.20** • Conservative PTS prevention and management – J. Matuska (CZ)
Q&A - Moderator: M. Monreal (SP) • Discussant: E. Aldrett Lee (MX)
- 7.40** • Procedural PTS prevention – A. Nicolaides (CY)
Q&A - Moderator: S. Kakkos (GR) • Discussant: J. Matuska (CZ)
- 7.55** • Take Home Messages – A. Nicolaides (CY)

EACCME (LEE21-01111)

October: **Thursday 7th** Focus on PAD/LEAD and DF
6.00-8.00 pm (CEST)

Plenary room: Challenges in clinical and procedural settings of PAD/LEAD and DF

- 6.00 • **Opening: current challenges in PAD** – A. Mansilha (PT)
Q&A - Moderator: J.D. Raffetto (US) • Discussant: J. Strejcek (CZ)
- 6.20 • **Which drivers for therapeutic strategies in PAD?** – A. Jawien (PL)
Q&A - Moderator: A. Mansilha (PT) • Discussant: J. Madaric (SL)
- 6.40 • **Challenges in DF clinical management** – A. Piaggese (IT)
Q&A - Moderator: A. Jawien (PL) • Discussant: S. Stanciu (RO)

New insights in the management of PAD/LEAD and DF

- 7.00 • **News from literature for PAD and DF management** – J.D. Raffetto (US)
Q&A - Moderator: A. Jawien (PL) • Discussant: J. Madaric (SL)
- 7.20 • **Insights from Guidelines in PAD and DF management** – Z. Krasinski (PL)
Q&A - Moderator: S. Stanciu (RO) • Discussant: J. Strejcek (CZ)
- 7.40 • **Peri-procedural management in DF revascularization** – A. Piaggese (IT)
Q&A - Moderator: A. Mansilha (PT) • Discussant: S. Stanciu (RO)
- 7.55 • **Take Home Messages** – A. Mansilha (PT)

EACCME (LEE21-01384)

October: **Thursday 14th** Focus on DR
6.00-7.00 pm (CEST)

Challenges and new insights in clinical and procedural settings of Diabetic Retinopathy

- 6.00 • **Progression in DR and DME: new insights from literature** – A. Chebil (TN)
Q&A - Moderator: S. Salomone (IT) • Discussant: J. Gumprecht (PL)
- 6.20 • **Endothelial targeting in Diabetic Retinopathy** – S. Salomone (IT)
Q&A - Moderator: J. Gumprecht (PL) • Discussant: A. Chebil (TN)
- 6.40 • **Guidelines in Diabetic microangiopathies: state of the art and novelties** – J. Gumprecht (PL)
Q&A - Moderator: A. Chebil (TN) • Discussant: S. Salomone (IT)
- 6.55 • **Take Home Messages** – A. Chebil (TN)

October: **Thursday 21st** Focus on DN

12.00-1.00 pm (CEST)

Challenges and new insights in clinical and procedural settings of Diabetic Nephropathy

- 12.00** • **Current Challenges and new insights from literature in Diabetic Nephropathy – G.Gambaro (IT)**
Q&A - Moderator: **J. Matuska (CZ)** • Discussant: **J. Gumprecht (PL)**
- 12.20** • **The role of the interaction between endothelial cells and podocytes in the pathogenesis of DKD – F. Yu (CN)**
Q&A - Moderator: **F. Wang (CN)** • Discussant: **G. Gambaro (IT)**
- 12.40** • **Limb ischemic preconditioning protects against contrast-induced nephropathy via Renalase F. Wang (CN)**
Q&A - Moderator: **F. Yu (CN)** • Discussant: **J. Matuska (CZ)**
- 12.55** • **Take Home Messages – G. Gambaro (IT)**

FACULTY:

E. Aldrett Lee (MX), P.L. Antignani (IT), E. Bouskela (BR), J. Caprini (US), A. Chebil (TN), L. Chernukha (UA), S. Flores (MX), S. Gianesini (IT), G. Gambaro (IT), A. Gonzalez Ochoa (MX), J. Gumprecht (PL), M.N. Hassairi (TN), A. Jawien (PL), S. Kakkos (GR), Z. Krasinski (PL), Z. Lazarashvili (GE), N. Lecuona (MX), Y. Li (CN), J. Madaric (SL), F. Mannello (IT), A. Mansilha (PT), J. Matuska (CZ), M. Monreal (SP), A. Nicolaides (CY), S. Olariu (RO), G. Palareti (IT), A. Piaggese (IT), P. Prandoni (IT), R. Rial (SP), S. Rockson (US), J.D. Raffetto (US), S. Salomone (IT), J. Serralde (MX), G. Sokurenko (RU), S. Stanciu (RO), J. Strejcek (CZ), T. Urbanek (PL), F. Wang (CN), F.Yu (CN), L. Zhang (CN), A. Zielinski (PL)

Secretariat:

FORMEDICA
Scientific Learning

E-mail: ecm@formedica.it
Mobile phone: +39 375/6589213

**CME requested (EACCME)
Simultaneous translations available
(CHI, RUS, SPA)**



With the unrestricted grant of Alfasigma S.p.A.

ALFASIGMA 